Federal Circuit affirms Exelixis patents; generic competitor blocked until Jan 15, 2030

EXELIXIS, INC.

Court of Appeals affirmed validity of U.S. Patent Nos. 11,091,439, 11,091,440, 11,098,015.
FDA approval of MSN's ANDA effective no earlier than Jan 15, 2030, subject to appeals and exclusivity.
MSN's appeal on patent 11,298,349 dismissed as moot; that ruling vacated.
Separate litigation on patent 12,128,039 (expires Feb 2032) with trial set for Nov 2026.
Outcome protects Exelixis from generic competition until at least 2030.

Featured in Daily 8-K Digest

Selected #9 for 2026-08-31. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.